Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MannKind Breathes Easier After FDA Diabetes Safety Guidance

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs
Advertisement

Related Content

Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
MannKind Says Inhaled Insulin NDA On Track, Resumes Search For Partner
Lilly Drops Inhaled-Insulin Program With Alkermes

Topics

Advertisement
UsernamePublicRestriction

Register

PS004044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel